

In silico Evaluation of Single-Nucleotide Polymorphisms in *CHRNA7* and *GRIN1* Genes Related to Alzheimer's Disease

Abstract

Aim: The purpose of this study is to predict the possible impact of missense single-nucleotide polymorphisms (SNPs) in *CHRNA7* and *GRIN1* genes associated with AD on protein structure, function, and stabilization and to analyze gene–gene interactions via *in silico* methods. **Materials and Methods:** SIFT, PolyPhen-2, SNPsandGO, PROVEAN, SNAP2, PhD-SNP, and Meta-SNP were used to estimate high-risk SNPs. The impact of SNPs on protein stabilization was evaluated with I-Mutant 3.0 and MUPRO software. Three-dimensional models of amino acid changes were determined with the Project HOPE software. Furthermore, the gene–gene interactions were analyzed via GeneMANIA. **Results:** According to the results of 603 missense SNPs in the *CHRNA7* gene, rs142728508 (Y233C), rs12899798 (W77G), rs138222088 (R227H), rs140316734 (R227C), rs199633275 (P322R), rs199819119 (L29F), rs200147286 (Q49P), rs200908085 (Y115C), rs201094833 (Q61R), rs201473594 (N69D), rs201210785 (E195K), and rs368352998 (S48W) polymorphisms were predicted as deleterious. Similarly, rs193920837 (P117 L), rs3181457 (I540M), and rs201764643 (R217P) polymorphisms in the *GRIN1* were estimated as deleterious. **Conclusion:** It is thought that the results of this study will provide useful information to guide future diagnostic and experimental strategies for AD.

Keywords: Alzheimer's disease, *CHRNA7*, *GRIN1*, *in silico*, single-nucleotide polymorphism

Introduction

Alzheimer's disease (AD) is known as a neurodegenerative disease (ND) that causes neurochemical deficiency in some parts of the brain, accumulation of amyloid- β , decreased cholinergic neurons, and formation of neurofibrillary tangles. Furthermore, pathologically, it causes amyloid- β accumulation outside the cell, while accumulation of tau proteins is observed inside the cell.^[1-3] Lately, a range of research has reported that the amyloid- β peptide binds to the alpha 7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) on neuronal cell surfaces, which results in the precipitate of amyloid plaque formation in AD.^[4,5] *CHRNA7* gene encodes $\alpha 7$ nAChR which are ligand-gated ion channels and substantially expressed in neuronal tissues.^[6,7] Furthermore, the N-methyl-D-aspartate (NMDA) receptor is a subtype of glutamate receptors and

has been reported to be closely related to neuronal activities. *GRIN1* (glutamate ionotropic receptor NMDA type subunit 1) gene encodes the GluN1 of NMDA receptors.^[8]

Single-nucleotide polymorphisms (SNPs) are significant in investigating the risk of susceptibility to diseases and in detecting drug responses. Therefore, SNPs have a key role in the detection of ND.^[9,10] Among the SNP types, missense SNPs cause amino acid substitution. Depending on its location, this change can have significant impacts on protein structure, function, and stabilization. The possible deleterious effects of missense SNPs in *CHRNA7* and *GRIN1* genes that lead to amino acid changes on protein function and structure can be estimated with the help of *in silico* analysis software with different algorithms, and the results can further guide diagnostic and experimental strategies.

The aim of this study is to predict the possible impact of missense SNPs in *CHRNA7* ve *GRIN1* genes associated with

Arash Rezaeirad¹,
Ömer Faruk
Karasakal²,
Ebru Özkan Oktay³,
Mesut Karahan⁴

¹Molecular Biology Master's Degree, Institute of Science, Üsküdar University, ²Medical Laboratory Techniques, ³Laboratory Technology, ⁴Biomedical Device Technology, Vocational School of Health Services, Üsküdar University, Istanbul, Türkiye

Received : 14-11-2022
Accepted : 02-12-2022
Published : 28-03-2023

Orcid

Arash Rezaeirad {ORCID: 0000-0001-9006-200X}
Ömer Faruk Karasakal {ORCID: 0000-0001-7803-3249}
Ebru Özkan Oktay {ORCID: 0000-0002-0395-9845}
Mesut Karahan {ORCID: 0000-0002-8971-678X}

Address for correspondence:

Dr. Ömer Faruk Karasakal,
Mimar Sinan Mah. Selman-I
Pak Cad, Üsküdar Üniversitesi
Çarşı, Yerleşkesi, PK:
34664, Istanbul, Turkey.
E-mail: omerfaruk.karasakal@uskudar.edu.tr

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

Ethics committee approval: There is no need for ethics committee approval.

How to cite this article: Rezaeirad A, Karasakal ÖF, Oktay EÖ, Karahan M. *In silico* evaluation of single-nucleotide polymorphisms in *CHRNA7* and *GRIN1* genes related to Alzheimer's disease. J Neurobehav Sci 2023;10:22-8.

Access this article online

Website: www.jnbsjournal.com

DOI: 10.4103/jnbs.jnbs_31_22

Quick Response Code:



AD on protein structure, function, and stabilization and to analyze gene–gene interactions using *in silico* methods.

Materials and Methods

There is no need for ethics committee approval.

First, the SNPs in the *CHRNA7* and *GRIN1* genes were obtained from the NCBI dbSNP (<https://www.ncbi.nlm.nih.gov/snp/>). The sequences of the protein encoded by the *CHRNA7* and *GRIN1* genes were obtained from the UniProt (<https://www.uniprot.org/>). Second, publicly available software such as SIFT, PolyPhen-2 (HumDiv-HumVar), SNPs and GO, PROVEAN, SNAP2, PHD-SNP, and Meta-SNP were used to predict potentially harmful SNPs in *CHRNA7* and *GRIN1* genes. After, I-Mutant 3.0 and MuPro were used to estimate its effect on protein stabilization. Furthermore, three-dimensional (3D) modeling of proteins was created by the Project HOPE. Finally, the gene–gene interactions were determined with the GeneMANIA (<https://genemania.org/>) [Figure 1].

SIFT (Sorting Intolerant From Tolerant) predicts the impact of an amino acid substitution on the function of a protein according to the sequence similarity and physical features of amino acids.^[11] PolyPhen-2 (HumDiv, HumVar) is a software that estimates the effects of an amino acid replacement on the structure and function of a given protein based on physical and comparative features.^[12] SNPsandGO predicts whether a SNP is associated with diseases based on protein functional annotation.^[13] PROVEAN is a software that

makes a prediction on the impact of an amino acid change on the protein function.^[14] SNAP2 predicts the functional effects of amino acid substitution based on a “neural network.”^[15] Phd-SNP (Predictor of human Deleterious SNP) is defined as a predictor of harmful SNPs in humans. The Phd-SNP algorithm was used for estimating the effect of human SNPs in both coding and noncoding sites.^[16] The Meta-SNP was used to estimate whether a particular protein variation can be identified as disease-associated.^[17]

MUpro^[18] and I-Mutant 3.0^[19] are support vector machine-based tools that estimate protein stability alterations due to SNPs. 3D modeling of proteins is created by Project HOPE. It also reports data on features of residues at polymorphism sites.^[20] The interactions of *CHRNA7* and *GRIN1* genes with other genes were determined with the GeneMANIA software tool.^[21]

Results

Results of gene–gene interaction

It was determined that there were 161 links between them when the interaction of the *CHRNA7* gene with 20 genes was examined. The maximum associated five genes with *CHRNA7* were *MAPK15*, *ADCY6*, *MAPKAPK5*, *MAPK4*, and *MAPK6*. Similarly, 624 links were determined between *GRIN1* and 20 genes examined. *GRIN2A*, *GRIN2B*, *FBXO2*, *GRIN3A*, and *DRD1* genes were determined as the top five genes which have the maximum association with *GRIN1* [Figure 2] (GeneMANIA).

Results of *in silico* analysis of *CHRNA7* and *GRIN1* genes

SNPs information for the *CHRNA7* and *GRIN1* genes was accessed from the NCBI dbSNP in September 2021. The total number of SNPs belonging to the *CHRNA7* gene was 51693 and the number of missense SNPs was 603. A total of 913 different amino acid changes of these missense SNPs were determined. Among them, twelve missense SNPs were determined to be possibly harmful and the results of the analysis are showed in Table 1. For the *GRIN1* gene, 591 missense SNPs were determined




Figure 1: *In silico* analyses tools




Figure 2: Gene–gene interaction of *CHRNA7* and *GRIN1* genes

Table 1: Prediction results of SNPs in the *CHRNA7* and *GRIN1* genes

Gene name	SNP number	Amino acid change	SIFT	Score	PolyPhen-2 HumDiv	Score	PolyPhen-2 HumVar	Score	PROVEAN score	
CHRNA7	rs142728508	Y233C	Dlt	0	PD	1.000	PD	1.000	Dlt	
	rs12899798	W77G	Dlt	0	PD	1.000	PD	1.000	Dlt	
	rs138222088	R227H	Dlt	0.001	PD	1.000	PD	0.998	Dlt	
	rs140316734	R227C	Dlt	0	PD	1.000	PD	1.000	Dlt	
	rs199633275	P322R	Dlt	0.001	PD	1.000	PD	0.992	Dlt	
	rs199819119	L29F	Dlt	0.002	PD	1.000	PD	1.000	Dlt	
	rs200147286	Q49P	Dlt	0.024	PD	0.986	PD	0.983	Dlt	
	rs200908085	Y115C	Dlt	0.022	PD	1.000	PD	0.997	Dlt	
	rs201094833	Q61R	Dlt	0	PD	0.996	PD	0.977	Dlt	
	rs201210785	E195K	Dlt	0	PD	0.999	PD	0.986	Dlt	
GRIN1	rs368352998	S48W	Dlt	0	PD	1.000	PD	0.999	Dlt	
	rs201473594	N69D	Dlt	0.044	PD	0.982	PD	0.950	Dlt	
	rs193920837	P117L	Dlt	0	PD	1.000	PD	1.000	Dlt	
	rs3181457	I540M	Dlt	0.002	PD	0.999	PD	0.996	Dlt	
	rs201764643	R217P	Dlt	0	PD	1.000	PD	0.998	Dlt	
CHRNA7	-8.472	Disease	10	Disease	0.853	Effect	65	80%	Disease	8
	-10.612	Disease	10	Disease	0.885	Effect	90	95%	Disease	7
	-4.574	Disease	10	Disease	0.625	Effect	66	80%	Disease	7
	-7.398	Disease	10	Disease	0.761	Effect	61	80%	Disease	6
	-5.409	Disease	10	Disease	0.635	Effect	78	85%	Disease	3
	-3.293	Disease	10	Disease	0.720	Effect	2	53%	Disease	4
	-2.540	Disease	10	Disease	0.519	Effect	24	63%	Disease	1
	-7.538	Disease	10	Disease	0.883	Effect	30	66%	Disease	8
	-3.362	Disease	10	Disease	0.759	Effect	76	85%	Disease	7
	-3.675	Disease	10	Disease	0.792	Effect	57	75%	Disease	5
GRIN1	-5.724	Disease	10	Disease	0.778	Effect	7	53%	Disease	5
	-4.235	Disease	10	Disease	0.763	Effect	18	59%	Disease	5
	-7.801	Disease	10	Disease	0.773	Effect	64	80%	Disease	9
	-2.582	Disease	7	Disease	0.506	Effect	17	59%	Disease	8
	-5.362	Disease	9	Disease	0.634	Effect	80	91%	Disease	6

Legend: Reliability index, PD: Probably damaging, Dlt: Deleterious, SIFT: Sorting Intolerant From Tolerant, SNPs: Single-nucleotide polymorphisms

RI: Reliability index, PD: Probably damaging, Dlt: Deleterious, SIFT: Sorting Intolerant From Tolerant, SNPs: Single-nucleotide polymorphisms

among 13914 SNPs and 751 different amino acid changes were detected. Among them, three missense SNPs were

determined to be harmful, and the analysis results are given in Table 1.

Table 2: Stability results of *CHRNA7* and *GRIN1*

Gene name	SNP ID	Amino Acid change	I-Mutant 3.0	DDG (Kcal/mol)	RI	MUpro	DDG
<i>CHRNA7</i>	rs142728508	Y233C	Decrease	0.00	7	Decrease	-0.95518426
	rs12899798	W77G	Decrease	-2.74	9	Decrease	-1.8496217
	rs138222088	R227H	Decrease	-1.22	8	Decrease	-1.198904
	rs140316734	R227C	Decrease	-1.49	3	Decrease	-0.60266667
	rs199633275	P322R	Decrease	-0.24	3	Decrease	-1.1710044
	rs199819119	L29F	Decrease	0.72	4	Decrease	-1.3135187
	rs200147286	Q49P	Decrease	-0.60	1	Decrease	-1.5366824
	rs200908085	Y115C	Decrease	0.85	1	Decrease	-0.77705861
	rs201094833	Q61R	Decrease	-1.02	3	Decrease	-0.91951906
	rs201210785	E195K	Decrease	-1.06	4	Decrease	-1.2298417
	rs368352998	S48W	Increase	-0.32	0	Decrease	-0.38466246
	rs201473594	N69D	Decrease	-1.20	8	Decrease	-0.43114591
<i>GRIN1</i>	rs193920837	P117L	Decrease	-1.43	6	Decrease	-0.33774896
	rs3181457	I540M	Decrease	-0.79	8	Decrease	-1.0170584
	rs201764643	R217P	Decrease	-1.28	4	Decrease	-1.6345586

DDG: Delta Delta G, RI: Reliability index, SNP: Single-nucleotide polymorphism

Table 3: Features of amino acids at polymorphism sites

Gene	SNP ID	Amino acid substitution	Size	Charge	Hydrophobicity
<i>CHRNA7</i>	rs142728508	Y233C	Wild type >Mutant type	-	Wild type <Mutant type
	rs12899798	W77G	Wild type >Mutant type	-	Wild type >Mutant type
	rs138222088	R227H	Wild type >Mutant type	Wild type: Positive Mutant type: Neutral	-
	rs140316734	R227C	Wild type >Mutant type	Wild type: Positive Mutant type: Neutral	Wild type <Mutant type
	rs199633275	P322R	Wild type <Mutant type	Wild type: Neutral Mutant type: Positive	Wild type >Mutant type
	rs199819119	L29F	Wild type <Mutant type	-	-
	rs200147286	Q49P	Wild type >Mutant type	-	Wild type <Mutant type
	rs200908085	Y115C	Wild type >Mutant type	-	Wild type <Mutant type
	rs201094833	Q61R	Wild type <Mutant type	Wild type: Neutral Mutant type: Positive	-
	rs201210785	E195K	Wild type <Mutant type	Wild type: Negative Mutant type: Positive	-
	rs368352998	S48W	Wild type <Mutant type	-	Wild type <Mutant type
<i>GRIN1</i>	rs193920837	P117L	Wild type <Mutant type	-	-
	rs3181457	I540M	Wild type <Mutant type	-	-
	rs201764643	R217P	Wild type >Mutant type	Wild type: Positive Mutant type: Neutral	Wild type <Mutant type

SNP: Single-nucleotide polymorphism

Results of protein stability

Stability analysis of proteins was performed with the I-Mutant 3.0 and MUpro software tools for variants that all online software tools predicted to be functionally harmful. The prediction results of are shown in Table 2.

Results of amino acids at polymorphism sites and three-dimensional models

The features of amino acid changes caused by variants in *CHRNA7* and *GRIN1* genes on protein structure and function were obtained with Project HOPE. The size, hydrophobicity, and charge differences between wild and variant amino acids as well as 3D structures of the protein were estimated. The results are given in Tables 3 and 4, respectively.

Discussion

In recent years, polymorphisms in the *CHRNA7* and *GRIN1* genes, which are associated with AD, have been the focus of attention. For example, the roles of polymorphisms in the *CHRNA7* gene in response to inhibitors in AD^[22,23] and polymorphisms in the *CHRNA7* gene in AD^[24] have been reported. Furthermore, the association studies between variations in the *GRIN1* gene and in various diseases such as type 2 diabetes mellitus,^[25] paranoid schizophrenia,^[26] and Parkinson's disease^[27] have been reported. In this

study, the possible effects of polymorphisms in these genes were determined by bioinformatics approach based on their roles on various diseases. The high-risk SNPs predicted using bioinformatics tools are rs142728508 (Y233C), rs12899798 (W77G), rs138222088 (R227H), rs140316734 (R227C), rs199633275 (P322R), rs199819119 (L29F) rs200147286 (Q49P), rs200908085 (Y115C), rs201094833 (Q61R), rs201210785 (E195K), and rs368352998 (S48W) in the *CHRNA7* gene and rs193920837 (P117 L), rs3181457 (I540M), and rs201764643 (R217P) in the *GRIN1* gene in this study.

The differences of features between wild and variant type amino acids of amino acid substitutions were investigated via Project HOPE [Table 3]. The protein stability changes caused by amino acid substitutions were estimated via I-Mutant and MUpro [Table 2]. Amino acid changes can affect the folding rate of a protein and depend mainly on the location and type of mutations.^[28] Amino acid substitutions can alter the function of a protein with disruption of hydrogen bonds or salt bridges, changing of the physicochemical effects, and geometric constraint changes. These changes may cause destabilization of protein or some abnormal biological functions.^[29]

The investigation of gene–gene interactions is significant in the etiology of some diseases such as cancer, cardiovascular, and immune system.^[30] For this reason,

Table 4: Project HOPE results of proteins encoded by *CHRNA7* and *GRIN1* genes

<i>CHRNA7</i>					
E195K				L29F	
Q49P				Y115C	
Y233C				S48W	
R227H				R227C	
P322R				Q61R	
W77G				N69D	
<i>GRIN1</i>					
P117L				I540M	
R217P					

gene–gene interaction map was determined in terms of genetic interaction, physical interaction, coexpression, colocalization, shared protein domains, pathways, and predicted interaction in *CHRNA7* and *GRIN1* genes [Figure 2].^[31]

Conclusion

Consequently, it is recommended that SNPs, which are predicted to be high risk in *CHRNA7* and *GRIN1* genes as a result of bioinformatic analyses carried out, should be primarily evaluated and investigated in experimental and clinical studies related to AD. For this reason, it is thought that the findings obtained from the study will provide important data for future experimental studies.

Patient informed consent

There is no need for patient informed consent

Ethics committee approval

There is no need for ethics committee approval.

Financial support and sponsorship

No funding was received.

Conflicts of interest

There are no conflicts of interest to declare.

Author contribution subject and rate

- Arash Rezaeirad (40%): Data collection, in silico analysis, writing—original draft preparation
- Ömer Faruk Karasakal (30%): Organizing the research, designing the research and methodology, writing (review and editing).
- Ebru Özkan Oktay (15%): Writing (review and editing), contributed with comments on methodology.
- Mesut Karahan (15%): Writing (review and editing), contributed with comments on methodology.

References

1. Sumirtanurdin R, Thalib AY, Cantona K, Abdulah R. Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: An update. *Clin Interv Aging* 2019;14:631-42. [DOI: 10.2147/CIA.S200109].
2. Noor A, Zahid S. A review of the role of synaptosomal-associated protein 25 (SNAP-25) in neurological disorders. *Int J Neurosci* 2017;127:805-11. [DOI: 10.1080/00207454.2016.1248240].
3. Guerini FR, Farina E, Costa AS, Baglio F, Saibene FL, Margaritella N, et al. ApoE and SNAP-25 polymorphisms predict the outcome of multidimensional stimulation therapy rehabilitation in Alzheimer's disease. *Neurorehabil Neural Repair* 2016;30:883-93. [DOI: 10.1177/1545968316642523].
4. Barabash A, Marcos A, Ancin I, Vázquez-Alvarez B, de Ugarte C, Gil P, et al. APOE, ACT and CHRNA7 genes in the conversion from amnesic mild cognitive impairment to Alzheimer's disease. *Neurobiol Aging* 2009;30:1254-64. [DOI: 10.1016/j.neurobiolaging. 2007.11.003].
5. Wang HY, Lee DH, Davis CB, Shank RP. Amyloid peptide Abeta (1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. *J Neurochem* 2000;75:1155-61. [DOI: 10.1046/j. 1471-4159.2000.0751155.x].
6. Pattanaik B, Hammarlund M, Mjörnstedt F, Ulleryd MA, Zhong W, Uhlén M, et al. Polymorphisms in alpha 7 nicotinic acetylcholine receptor gene, CHRNA7, and its partially duplicated gene, CHRFAM7A, associate with increased inflammatory response in human peripheral mononuclear cells. *FASEB J* 2022;36:e22271. [DOI: 10.1096/fj. 202101898R].
7. Sinkus ML, Graw S, Freedman R, Ross RG, Lester HA, Leonard S. The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function. *Neuropharmacology* 2015;96:274-88. [DOI: 10.1016/j.neuropharm. 2015.02.006].
8. Liu YP, Wu X, Meng JH, Yao J, Wang BJ. Functional analysis of the 3' untranslated region of the human GRIN1 gene in regulating gene expression *in vitro*. *Neuropsychiatr Dis Treat* 2020;16:2361-70. [DOI: 10.2147/NDT.S268753].
9. Amber S, Zahid S. Data integration for functional annotation of regulatory single nucleotide polymorphisms associated with Alzheimer's disease susceptibility. *Gene* 2018;672:115-25. [DOI: 10.1016/j.gene. 2018.06.011].
10. Alwi ZB. The use of SNPs in pharmacogenomics studies. *Malays J Med Sci* 2005;12:4-12.
11. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. *Nucleic Acids Res* 2003;31:3812-4. [DOI: 10.1093/nar/gkg509].
12. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet* 2013;Chapter 7:Unit7.20. [DOI: 10.1002/0471142905.hg0720s76].
13. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations improve the predictive score of human disease-related mutations in proteins. *Hum Mutat* 2009;30:1237-44. [DOI: 10.1002/humu. 21047].
14. Choi Y, Chan AP. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics* 2015;31:2745-7. [DOI: 10.1093/bioinformatics/ btv195].
15. Hecht M, Bromberg Y, Rost B. Better prediction of functional effects for sequence variants. *BMC Genomics* 2015;16 Suppl 8:S1. [DOI: 10.1186/1471-2164-16-S8-S1].
16. Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. *Bioinformatics* 2006;22:2729-34. [DOI: 10.1093/bioinformatics/btl423].
17. Capriotti E, Altman RB, Bromberg Y. Collective judgment predicts disease-associated single nucleotide variants. *BMC Genomics* 2013;14 Suppl 3:S2. [DOI: 10.1186/1471-2164-14-S3-S2].
18. Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. *Proteins* 2006;62:1125-32. [DOI: 10.1002/prot. 20810].
19. Capriotti E, Fariselli P, Casadio R. I-mutant2.0: Predicting stability changes upon mutation from the protein sequence or structure. *Nucleic Acids Res* 2005;33:W306-10. [DOI: 10.1093/nar/gki375].
20. Venselaar H, Te Beek TA, Kuipers RK, Hekkelman ML, Vriend G. Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces. *BMC Bioinformatics* 2010;11:548. [DOI: 10.1186/1471-2105-11-548].
21. Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL, et al. GeneMANIA Cytoscape plugin: Fast

- gene function predictions on the desktop. *Bioinformatics* 2010;26:2927-8. [DOI: 10.1093/bioinformatics/btq562].
22. Russo P, Kisialiou A, Moroni R, Prinzi G, Fini M. Effect of genetic polymorphisms (SNPs) in *CHRNA7* gene on response to acetylcholinesterase inhibitors (AChEI) in patients with Alzheimer's disease. *Curr Drug Targets* 2017;18:1179-90. [DOI: 10.2174/1389450116666151001111826].
23. Clarelli F, Mascia E, Santangelo R, Mazzeo S, Giacalone G, Galimberti D, *et al.* *CHRNA7* gene and response to cholinesterase inhibitors in an Italian cohort of Alzheimer's disease patients. *J Alzheimers Dis* 2016;52:1203-8. [DOI: 10.3233/JAD-160074].
24. Mohammadi S, Mahmoudi J, Farajdokht F, Asadi M, Pirsarabi P, Kazeminaei SF, *et al.* Polymorphisms of nicotinic acetylcholine receptors in Alzheimer's disease: A systematic review and data analysis. *Egypt J Med Hum Genet* 2022;23:144. [doi.org/10.1186/s43042-022-00357-y].
25. Kochetova OV, Avzaletdinova DS, Korytina GF, Morugova TV, Mustafina OE. The association between eating behavior and polymorphisms in *GRIN2B*, *GRIK3*, *GRI1A1* and *GRIN1* genes in people with type 2 diabetes mellitus. *Mol Biol Rep* 2020;47:2035-46. [doi.org/10.1007/s11033-020-05304-x].
26. Li ZJ, Ding M, Pang H, Sun XF, Xing JX, Xuan JF, *et al.* Correlation between genetic polymorphisms of -855 G/C and -1140 G/A in *GRIN1* gene and paranoid schizophrenia. *Fa Yi Xue Za Zhi* 2013;29:107-9.
27. Wu SL, Wang WF, Shyu HY, Ho YJ, Shieh JC, Fu YP, *et al.* Association analysis of *GRIN1* and *GRIN2B* polymorphisms and Parkinson's disease in a hospital-based case-control study. *Neurosci Lett* 2010;478:61-5. [DOI: 10.1016/j.neulet.2010.04.063].
28. Gromiha MM, Nagarajan R, Selvaraj S. Protein structural bioinformatics: An overview. *Encyclopedia of Bioinformatics and Computational Biology* 2019;2:445-59. [DOI: https://doi.org/10.1016/B978-0-12-809633-8.20278-1].
29. Teng S, Srivastava AK, Wang L. Sequence feature-based prediction of protein stability changes upon amino acid substitutions. *BMC Genomics* 2010;11 Suppl 2:S5. [DOI: 10.1186/1471-2164-11-S2-S5].
30. Rajapakse I, Perlman MD, Martin PJ, Hansen JA, Kooperberg C. Multivariate detection of gene-gene interactions. *Genet Epidemiol* 2012;36:622-30. [DOI: 10.1002/gepi.21656].
31. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, *et al.* The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 2010;38:W214-20. [DOI: 10.1093/nar/gkq537].